Document is current

Any future updates will be listed below

First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA

Crossref DOI link: https://doi.org/10.1038/s41571-026-01169-4

Published Online: 2026-06-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark